Skip to main content
Premium Trial:

Request an Annual Quote

Celera Gets $900K From NIH to Develop Avian Flu Dx; Abbott to Sell Assay

NEW YORK (GenomeWeb News) – Celera Genomics today said it has received $900,000 from the US National Institutes of Health to develop and commercialize an in vitro diagnostic for detect the A/H5 influenza virus.
Celera said it plans to develop the test using the primer, probe set, and protocols used by US Health and Human Services' Centers for Disease Control and Prevention, whose IP was recently cleared by the US Food and Drug Administration.
Celera said it will license the CDC’s H5N1 assay information and sell the test through its alliance with Abbott.
Celera said it expects the test to run on Abbott's new m2000 system for detecting and monitoring infectious diseases and use automated real-time PCR technology from Applied Biosystems.
The m2000 is currently available in Europe with CE Mark certification and is pending 510(k) clearance with the FDA.
The CDC’s assay is the only FDA-cleared test that detects the H5N1 virus, and its use is limited to labs designated by the Laboratory Response Network, Celera said.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.